Klaudia Krawczyńska

Ms. Klaudia Krawczyńska

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in Translational Oncology
Verified
Journal Article
Open access
Agnieszka RusakAgnieszka Rusak
Agnieszka Rusak
Benita WiatrakBenita Wiatrak
Benita Wiatrak
Klaudia KrawczyńskaKlaudia Krawczyńska
Klaudia Krawczyńska
TGTomasz Górnicki
Tomasz Górnicki
KZKarol Zagórski
Karol Zagórski
WFWojciech Fortuna
Wojciech Fortuna
Glioblastoma multiforme (GBM) is one of the most aggressive and lethal brain tumors, characterized by rapid growth, invasiveness, and resistance to standard therapies, including surgery, chemotherapy, and radiotherapy. Despite advances in treatment, GBM remains highly resistant due to its complex molecular mechanisms, including angiogenesis, invasion, immune modulation, and lipid metabolism dysregulation. This review explores recent breakthroughs in targeted therapies, focusing on innovative drug carriers such as nanoparticles and liposomes, and their potential to overcome GBM's chemo- and radioresistant phenotypes. We also discuss the molecular pathways involved in GBM progression and the latest therapeutic strategies, including immunotherapy and precision medicine approaches, which hold promise for improving clinical outcomes. The review highlights the importance of understanding GBM's genetic and molecular heterogeneity to develop more effective, personalized treatment protocols aimed at increasing survival rates and enhancing the quality of life for GBM patients.

18 April 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Klaudia KrawczyńskaKlaudia Krawczyńska
Klaudia Krawczyńska
ARAgnieszka Rusak
Agnieszka Rusak
TGTomasz Górnicki
Tomasz Górnicki
MMMonika Mrozowska
Monika Mrozowska
PDPiotr DzięGiel
Piotr DzięGiel
JGJerzy Gubernator
Jerzy Gubernator
Quercetin is a chemical compound present in many fruits and vegetables, known for its antioxidant and anti-inflammatory effects. Additionally, this bioactive flavonoid can induce apoptosis in abnormally developing cells. The aim of the study was to develop an effective method for encapsulating quercetin in liposomes and to evaluate the drug encapsulation efficiency, stability of the formulation and anticancer effects on melanoma cells. The results showed that quercetin can be successfully encapsulated in the aqueous phase of liposomes by complexing it with copper ions. To assess the cytotoxicity of the liposomal quercetin, SRB assays were performed on two melanoma cell lines, A-375 and C32, as well as on normal human keratinocytes, HaCaT. This formulation exhibited a cytotoxic effect on melanotic melanoma cells but not on normal cells, indicating the possible use of liposomal quercetin in anticancer treatment.

14 September 2024 in Cells
Verified
Journal Article
Open access
PDF file
TGTomasz Górnicki
Tomasz Górnicki
JLJakub Lambrinow
Jakub Lambrinow
MMMonika Mrozowska
Monika Mrozowska
Klaudia KrawczyńskaKlaudia Krawczyńska
Klaudia Krawczyńska
NSNatalia Staszko
Natalia Staszko
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
Epithelial-to-mesenchymal transition (EMT) is a complex cellular process that allows cells to change their phenotype from epithelial to mesenchymal-like. Type 3 EMT occurs during cancer progression. The aim of this study was to investigate the role of RNA-binding motif single-stranded interacting protein 3 (RBMS 3) in the process of EMT. To investigate the impact of RBMS 3 on EMT, we performed immunohistochemical (IHC) reactions on archived paraffin blocks of invasive ductal breast carcinoma (n = 449), allowing us to analyze the correlation in expression between RBMS 3 and common markers of EMT. The IHC results confirmed the association of RBMS 3 with EMT markers. Furthermore, we performed an in vitro study using cellular models of triple negative and HER-2-enriched breast cancer with the overexpression and silencing of RBMS 3. RT-qPCR and Western blot methods were used to detect changes at both the mRNA and protein levels. An invasion assay and confocal microscopy were used to study the migratory potential of cells depending on the RBMS 3 expression. The studies conducted suggest that RBMS 3 may potentially act as an EMT-promoting agent in the most aggressive subtype of breast cancer, triple negative breast cancer (TNBC), but as an EMT suppressor in the HER-2-enriched subtype. The results of this study indicate the complex role of RBMS 3 in regulating the EMT process and present it as a future potential target for personalized therapies and a diagnostic marker in breast cancer.

1 November 2012 in European Journal of Cancer
Verified
Journal Article
Closed access
KBK. Brzozka
K. Brzozka
RWR. Windak
R. Windak
KPK. Prymula
K. Prymula
MMM. Milik
M. Milik
AKA. Klosowska
A. Klosowska
WCW. Czardybon
W. Czardybon

Verified
Journal Article
Open access
PDF file
MOMateusz Olbromski
Mateusz Olbromski
APAleksandra Piotrowska
Aleksandra Piotrowska
MMMonika Mrozowska
Monika Mrozowska
AKAlicja Kmiecik
Alicja Kmiecik
NGNatalia Malgorzata Glatzel-Plucinska
Natalia Malgorzata Glatzel-Plucinska
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
SOX (SRY-related HMG-box) transcription factors are key regulators of embryogenesis and vascular development, with emerging roles in cancer biology. In non-small-cell lung cancer (NSCLC), the contributions of SOX18 and SOX30 remain insufficiently understood, particularly regarding their epigenetic regulation and network interactions with angiogenic and immune-modulatory pathways. We examined 800 NSCLC specimens (400 lung adenocarcinomas, 400 squamous cell carcinomas) using immunohistochemistry, RT-qPCR, Western blotting, and spatial transcriptomics to profile SOX18, SOX30, and related signaling partners (SOX7, SOX17, MEF2C—Myocyte Enhancer Factor 2C, VCAM1—Vascular Cell Adhesion Molecule 1, p-STAT3—Signal Transducer and Activator of Transcription 3). Epigenetic regulation was assessed via droplet digital methylation-specific PCR of promoter CpG islands, while functional validation employed adenoviral delivery of hsa-miR-24-3p in NSCLC cell lines and 3D spheroid cultures. SOX18 protein was markedly overexpressed in both NSCLC subtypes, despite reduced transcript levels and consistent promoter hypermethylation, suggesting post-transcriptional regulation. In contrast, SOX30 expression was uniformly downregulated at both mRNA and protein levels, frequently linked to promoter hypermethylation, especially in squamous carcinoma. Spatial transcriptomics revealed SOX18 enrichment at tumor cores and invasive borders, co-localizing with MEF2C, VCAM1, and p-STAT3 in vascular and stromal niches, while SOX30 expression remained low across all tumor regions. Functional assays demonstrated that hsa-miR-24-3p suppressed SOX18 expression and partially modulated SOX30 and MEF2C, reinforcing a miRNA-driven regulatory axis. In summary, SOX18 and SOX30 play divergent roles in NSCLC progression: SOX18 functions as a pro-oncogenic factor driving angiogenesis and tumor–stroma interactions, while SOX30 acts as an epigenetically silenced tumor suppressor. Regulation of SOX18 by miR-24-3p highlights a potential therapeutic vulnerability. These findings underscore the significance of SOX transcription factors as biomarkers and potential targets for novel treatment strategies in NSCLC.